Considered as one of the greatest threats to mankind, infectious diseases are responsible for 15% of all deaths worldwide, and transmission rates remain high due to increasingly transient and concentrated global populations (source WHO). Through science and innovation, The Janssen Pharmaceutical Companies of Johnson & Johnson aims to deliver an end-to-end approach to prevent, treat and cure infectious diseases. It is our goal to ensure a future where we can hopefully prevent the spread of infectious diseases and eliminate the burden they place on global health, but we can’t do it alone.
Don't miss this lively discussion featuring leaders in the field who can share the opportunities and challenges of medicines aiming to help fight infectious diseases worldwide, as well as in Europe.
*This program is a product of a collaboration between Johnson & Johnson Innovation – JLABS (JLABS) and the Biomedical Advanced Research and Development Authority (BARDA), a component of the Office of the Assistant Secretary for Preparedness and Response in the U.S. Department of Health and Human Services.